Phathom Pharmaceuticals, Inc. PHAT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s accrued expenses?
- Phathom Pharmaceuticals, Inc. (PHAT) reported accrued expenses of $7.5M in Q4 2025.
- How has Phathom Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s accrued expenses decreased by 85.9% year-over-year, from $53.23M to $7.5M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s accrued expenses has grown at a -6.7% compound annual growth rate (CAGR), from $10.61M to $7.5M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.